Zydus Cadila gets DGCI nod for diabetes treatment drug
In India, the drug was previously approved in 2013 for the treatment of hypertriglyceridemia and diabetic dyslipidemia03-02-2020
03-02-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives approval from DCGI for Saroglitazar Magnesium for treatment of Type II Diabetes03-02-2020
CADILA HEALTHCARE LTD. - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of Loss of Share Certificate31-01-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Teleconference Call Post Announcement of Results on February 5, 202029-01-2020
CADILA HEALTHCARE LTD. - 532321 - Loss of Share Certificate / Issue of Duplicate Share Certificate
Loss of Share Certificate / Issue of Duplicate Share Certificate.28-01-2020
Zydus inks pact with China Medical System to market Desidustat in Greater China
Our Bureau Zydus Cadila has entered into a licensing agreement with China Medical System Holdings Ltd (CMS) for developing and commercialisation of20-01-2020
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus and China Medical System Holdings enter into a License Agreement for Desidustat in Greater China20-01-2020
Cadila Healthcare Ltd - 532321 - Board Meeting Intimation for Unaudited Financial Results For The Quarter / Nine Months Ended On December 31, 2019
CADILA HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/02/2020 ,inter alia, to consider and approve Unaudited Financial Results for the quarter / nine months ended on December 31, 201917-01-2020
Cadila Healthcare Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate / issue of duplicate share certificate under regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)08-01-2020
Cadila Healthcare Ltd - 532321 - Statement Of Investor Complaints For The Quarter Ended December 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0440 Name of the Signatory :- Dhaval N SoniDesignation :- Company Secretary and Compliance Officer07-01-2020